HUGE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:49):

Stats
Today's Volume	1.16M
Average Volume	210 196
Market Cap	14.85M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.800
ATR14	$0.00100 (0.27%)

Volume Correlation

Long: -0.16 (neutral)

Short: 0.62 (weak)

Signal:(41.284) Neutral

FSD Pharma Inc Correlation

10 Most Positive Correlations
APVO	0.948
VGFC	0.944
SHEN	0.943
WKSP	0.943
MBIN	0.941
GMVD	0.938
JRJC	0.934
MIGI	0.933
TREE	0.932
GLPG	0.932

10 Most Negative Correlations
IVCB	-0.945
AEYE	-0.941
ALSA	-0.939
MSSA	-0.939
TZPS	-0.939
TZPSU	-0.933
MPRA	-0.932
MLAI	-0.93
VITL	-0.929
VCTR	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FSD Pharma Inc Correlation - Currency/Commodity

0.00
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.04
( neutral )

FSD Pharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.55M (0.00 %)
EPS:	$-0.470

FY	2023
Revenue:	$0
Gross Profit:	$-2.55M (0.00 %)
EPS:	$-0.470

FY	2022
Revenue:	$0
Gross Profit:	$-4.36M (0.00 %)
EPS:	$-0.600

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

FSD Pharma Inc

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.